Drug-Drug Interaction Clinical Decision Support Conference Series
药物-药物相互作用临床决策支持会议系列
基本信息
- 批准号:8431860
- 负责人:
- 金额:$ 10万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-09-30 至 2015-09-29
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): Medications are essential to preventing and treating many illnesses. Americans receive an average of 12, and those aged 65 years and older receive more than 30 prescriptions each year. This degree of medication use creates the potential for drug-drug interactions (DDIs). Injury due to a known DDI is a preventable adverse drug event and serious medication error. Evidence suggests that hundreds of millions of interacting drugs are co-prescribed each year, ultimately exposing hundreds of millions of patients to these known hazards. Although the exact magnitude of harm associated with DDIs is not known, clinically significant interactions occur, resulting in potentially life-threatening consequences. Electronic prescribing and pharmacy information systems include DDI alerts as a form of clinical decision support (CDS) to warn prescribers and pharmacists of potentially harmful medication combinations, and provide them with necessary information to avoid or mitigate the risk of patient harm. Today, every pharmacy and soon every physician office and health care organization will employ some form of health information technology that will include DDI alerts. However, use of this technology to improve patient safety has not lived up to its promise. In particular, research has shown "the current DDI alert system is broken." This application requests partial support for a solution-oriented conference series aimed at improving the implementation of meaningful DDI alerts within CDS. The long- term goals are to develop an ongoing structured process to improve the quality of DDI alerting systems used by health providers to maximize the value of this technology, and ultimately improve patient safety. At these conferences, experts, stakeholders, and public-private partnerships will develop strategies for explicit, systematic evaluation of DDIs to improve knowledge base data and the practical utility of electronic clinical decision aids. Specific aims of the conference series are to: 1) develop guidelines for systematic appraisal of DDI evidence; 2) recommend principles for including DDIs in drug safety alerts; and 3) establish preferred strategies for presenting DDI alerts. In summary, this application will address an important public health issue regarding improving health information technology as a healthcare safety net, and will, ultimately lead to improved medication use and patient safety throughout the nation.
PUBLIC HEALTH RELEVANCE: Hundreds of millions of potential drug interactions occur every year, affecting millions of patients. Drug interactions can be prevented and breakdowns in the healthcare system are to blame for many of these serious, and sometimes deadly, medical errors. This project will conduct four meetings with national and international experts to design better systems to prevent drug interactions, resulting in improved patient safety and health for all Americans.
描述(由申请人提供):药物对于预防和治疗许多疾病至关重要。美国人平均每年收到 12 张处方,65 岁及以上的老年人每年收到超过 30 张处方。这种程度的药物使用可能会产生药物相互作用 (DDI)。已知 DDI 造成的伤害是可预防的药物不良事件和严重用药错误。有证据表明,每年共同开出数亿种相互作用的药物,最终使数亿患者面临这些已知的危害。尽管 DDI 造成的确切危害程度尚不清楚,但临床上会发生显着的相互作用,从而导致潜在的危及生命的后果。电子处方和药房信息系统包括 DDI 警报,作为临床决策支持 (CDS) 的一种形式,用于警告处方者和药剂师潜在有害的药物组合,并向他们提供必要的信息,以避免或减轻患者伤害的风险。如今,每个药房以及很快每个医生办公室和医疗保健组织都将采用某种形式的健康信息技术,其中包括 DDI 警报。然而,利用这项技术来提高患者安全并没有兑现其承诺。特别是,研究表明“当前的 DDI 警报系统已损坏”。此应用程序请求对面向解决方案的会议系列提供部分支持,旨在改进 CDS 中有意义的 DDI 警报的实施。长期目标是开发一个持续的结构化流程,以提高医疗服务提供者使用的 DDI 警报系统的质量,从而最大限度地发挥该技术的价值,并最终提高患者的安全。在这些会议上,专家、利益相关者和公私合作伙伴将制定对 DDI 进行明确、系统评估的策略,以改进知识库数据和电子临床决策辅助的实际效用。该系列会议的具体目标是: 1) 制定 DDI 证据系统评估指南; 2) 建议将 DDI 纳入药品安全警报的原则; 3) 建立呈现 DDI 警报的首选策略。总之,该应用程序将解决一个重要的公共卫生问题,即改善健康信息技术作为医疗保健安全网,并最终改善全国范围内的药物使用和患者安全。
公共卫生相关性:每年都会发生数亿种潜在的药物相互作用,影响数百万患者。药物相互作用是可以预防的,而医疗保健系统的崩溃是许多严重的、有时甚至是致命的医疗错误的罪魁祸首。该项目将与国内和国际专家举行四次会议,设计更好的系统来防止药物相互作用,从而改善所有美国人的患者安全和健康。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DANIEL C MALONE其他文献
DANIEL C MALONE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DANIEL C MALONE', 18)}}的其他基金
Implementation of DDInteract: A Shared-decision Making Tool for Anticoagulant Drug-Drug INTERACTions
DDInteract 的实施:抗凝药物-药物相互作用的共享决策工具
- 批准号:
10628461 - 财政年份:2023
- 资助金额:
$ 10万 - 项目类别:
Enabling Shared Decision Making to Reduce Harm from Drug Interactions: An End-to-End Demonstration
实现共同决策以减少药物相互作用的危害:端到端演示
- 批准号:
10023271 - 财政年份:2019
- 资助金额:
$ 10万 - 项目类别:
Dissemination and Implementation of QT Risk Clinical Decision Support
QT 风险临床决策支持的传播和实施
- 批准号:
9901452 - 财政年份:2019
- 资助金额:
$ 10万 - 项目类别:
Dissemination and Implementation of QT Risk Clinical Decision Support
QT 风险临床决策支持的传播和实施
- 批准号:
10103922 - 财政年份:2019
- 资助金额:
$ 10万 - 项目类别:
Drug-Drug Interaction Clinical Decision Support Conference Series
药物-药物相互作用临床决策支持会议系列
- 批准号:
8730131 - 财政年份:2012
- 资助金额:
$ 10万 - 项目类别:
Drug-Drug Interaction Clinical Decision Support Conference Series
药物-药物相互作用临床决策支持会议系列
- 批准号:
8550787 - 财政年份:2012
- 资助金额:
$ 10万 - 项目类别:
Innovative Diffusion of Comparative Effectiveness Research
比较有效性研究的创新传播
- 批准号:
8007568 - 财政年份:2010
- 资助金额:
$ 10万 - 项目类别:
相似国自然基金
基于interaction和backbone的NP类MAS问题解集表示、复杂性统计与高效算法研究
- 批准号:11201019
- 批准年份:2012
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
Reality-based Interaction用户界面模型和评估方法研究
- 批准号:61170182
- 批准年份:2011
- 资助金额:57.0 万元
- 项目类别:面上项目
Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data
- 批准号:31070748
- 批准年份:2010
- 资助金额:34.0 万元
- 项目类别:面上项目
相似海外基金
Evidence-based Drug-Interaction Discovery: In-Vivo, In-Vitro and Clinical
基于证据的药物相互作用发现:体内、体外和临床
- 批准号:
9336353 - 财政年份:2014
- 资助金额:
$ 10万 - 项目类别:
Evidence-based Drug-Interaction Discovery: In-Vivo, In-Vitro and Clinical
基于证据的药物相互作用发现:体内、体外和临床
- 批准号:
9119045 - 财政年份:2014
- 资助金额:
$ 10万 - 项目类别:
Basic study for appropriate use of clinical medicine: functional interaction of drug metabolizing enzymes and its significance in vivo
临床用药的基础研究:药物代谢酶的功能相互作用及其体内意义
- 批准号:
25293039 - 财政年份:2013
- 资助金额:
$ 10万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Drug-Drug Interaction Clinical Decision Support Conference Series
药物-药物相互作用临床决策支持会议系列
- 批准号:
8730131 - 财政年份:2012
- 资助金额:
$ 10万 - 项目类别:
Drug-Drug Interaction Clinical Decision Support Conference Series
药物-药物相互作用临床决策支持会议系列
- 批准号:
8550787 - 财政年份:2012
- 资助金额:
$ 10万 - 项目类别:
Clinical importance of the drug interaction between statins and SYP3A inhibitors
他汀类药物与 SYP3A 抑制剂之间药物相互作用的临床重要性
- 批准号:
7633266 - 财政年份:2008
- 资助金额:
$ 10万 - 项目类别:
PHASE 1 MULTIPLE-DOSE SAFETY, PHARMACOKINETIC, AND DRUG INTERACTION CLINICAL STU
第一阶段多剂量安全性、药代动力学和药物相互作用临床研究
- 批准号:
7543353 - 财政年份:2003
- 资助金额:
$ 10万 - 项目类别:














{{item.name}}会员




